(2S,3R,4R,5S)-2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol

ID: ALA568164

Chembl Id: CHEMBL568164

Cas Number: 1018898-94-6

PubChem CID: 44479924

Max Phase: Preclinical

Molecular Formula: C19H21ClO6

Molecular Weight: 380.82

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COC1O[C@@H](c2ccc(Cl)c(Cc3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C19H21ClO6/c1-25-19-17(24)15(22)16(23)18(26-19)11-4-7-14(20)12(9-11)8-10-2-5-13(21)6-3-10/h2-7,9,15-19,21-24H,8H2,1H3/t15-,16-,17+,18+,19?/m1/s1

Standard InChI Key:  YSQLKZLRLCWBQK-OKLPXFMBSA-N

Associated Targets(Human)

SLC5A2 Tclin Sodium/glucose cotransporter 2 (2000 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Slc5a2 Sodium/glucose cotransporter 2 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 380.82Molecular Weight (Monoisotopic): 380.1027AlogP: 1.76#Rotatable Bonds: 4
Polar Surface Area: 99.38Molecular Species: NEUTRALHBA: 6HBD: 4
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 10.11CX Basic pKa: CX LogP: 2.52CX LogD: 2.52
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.64Np Likeness Score: 1.07

References

1. Goodwin NC, Mabon R, Harrison BA, Shadoan MK, Almstead ZY, Xie Y, Healy J, Buhring LM, DaCosta CM, Bardenhagen J, Mseeh F, Liu Q, Nouraldeen A, Wilson AG, Kimball SD, Powell DR, Rawlins DB..  (2009)  Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,  52  (20): [PMID:19785435] [10.1021/jm900951n]

Source